UNSPSC 51102842: Dalfopristin/quinupristin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM900. This VA Drug Class (AM900) classifies this compound as belonging to the group ANTI-INFECTIVES, OTHER.

UNSPSC 51102842 Dalfopristin/quinupristin is a Commodity code for a specific antibiotic pharmaceutical product, though recent state and local procurement activity tagged under this code shows minimal direct alignment with the code's nominal scope. The Illinois Department of Public Health's August 2026 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium awarded to Chartwell Rx LLC supplied Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets rather than dalfopristin/quinupristin, and Seminole County, Florida's June 2026 bid solicited naloxone and safe drug deactivation systems—neither matching the code's specific antibiotic designation. State and local governments soliciting under this code appear to use it as a catch-all taxonomy marker for pharmaceutical procurement rather than as a precise product-line identifier, with issuing bodies ranging from state health departments to county purchasing offices managing drug supply contracts through cooperative purchasing vehicles and traditional competitive bidding processes.

The code shows activity in Illinois and Florida within the recent opportunities record, though the sample is too narrow to characterize broader geographic concentration. The Illinois Department of Public Health contract, valued at $2,999,999.11 over the life of the agreement including renewals, represents a 12-month initial term with two optional renewal years and was awarded through an Invitation for Bid process to the lowest priced responsive and responsible bidder with no set-asides applied. Seminole County's procurement (IFB 60459723LAS), posted June 30, 2026 with a July 26, 2026 response deadline, sought annual volumes of 1,900 naloxone units and 800 deactivation systems with quarterly delivery to the county's community health building, fixed-fee pricing, a two-year initial term with one-year renewal option, and potential FEMA funding subject to federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. The code's recent activity is sparse and primarily reflects pharmaceutical supply contracts under state and local health procurement rather than dalfopristin/quinupristin-specific demand.